Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 8/20 | 0.41 |
| ▸ | MAOA | P21397 | 6/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680803 | 1.00 | HTR2C (0.58) | HTR2CMTNR1BMTNR1AMAOBMAOA | |
| SCHEMBL4682225 | 0.95 | HTR2C (0.59) | HTR2CMTNR1BMTNR1AMAOBMAOA | |
| SCHEMBL4682222 | 0.95 | HTR2C (0.59) | HTR2CMTNR1BMTNR1AMAOBMAOA | |
| SCHEMBL4681941 | 0.90 | HTR2C (0.66) | HTR2CMAOBS1PR1 | |
| SCHEMBL4681939 | 0.90 | HTR2C (0.66) | HTR2CMAOBS1PR1 | |
| Hydrochloric Acid SCHEMBL4681309 | 0.89 | HTR2C (0.65) | HTR2CMAOBS1PR1 | |
| Hydrochloric Acid SCHEMBL4681302 | 0.89 | HTR2C (0.65) | HTR2CMAOBS1PR1 | |
| SCHEMBL4681717 | 0.88 | HTR2C (0.50) | HTR2C | |
| SCHEMBL4681721 | 0.88 | HTR2C (0.50) | HTR2C | |
| SCHEMBL4681102 | 0.87 | DPP4 (0.43) | HTR2CMTNR1BMTNR1AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | HTR2C 289/4885MTNR1B 492/4885MTNR1A 595/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | HTR2C 289/4885MTNR1B 492/4885MTNR1A 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.